What is the appropriate starting dose of Suboxone (buprenorphine/naloxone) for an adult with opioid use disorder who is in moderate opioid withdrawal?

Starting Dose of Suboxone for Opioid Use Disorder

For adults with opioid use disorder in moderate withdrawal (COWS ≥8), start with 4–8 mg sublingual buprenorphine-naloxone as the initial dose, reassess after 30–60 minutes, and give additional 2–4 mg doses every 2 hours as needed to target a Day 1 total of approximately 8 mg, followed by 16 mg daily as the standard maintenance dose. 1

Pre-Induction Requirements

Before administering the first dose, you must verify three critical safety criteria:

• Confirm adequate time since last opioid use: wait >12 hours after short-acting opioids (heroin, immediate-release oxycodone/morphine, fentanyl), >24 hours after extended-release formulations (OxyContin), and >72 hours after methadone maintenance 1

• Document moderate-to-severe withdrawal using COWS: only initiate when the Clinical Opiate Withdrawal Scale score is ≥8; scores of 5–12 indicate mild withdrawal and buprenorphine should be deferred 1

• Screen for contraindicated medications: identify QT-prolonging drugs (absolute contraindication) and high-dose benzodiazepines (FDA black-box warning for fatal respiratory depression) 1, 2

The American College of Emergency Physicians emphasizes that administering buprenorphine when COWS <8 will precipitate severe withdrawal because buprenorphine's high receptor affinity displaces residual full-agonist opioids still occupying mu-receptors 1.

Day 1 Induction Protocol

Initial dose algorithm:

• Give 4 mg sublingual if COWS 8–12 (moderate withdrawal) 1
• Give 8 mg sublingual if COWS ≥13 (moderately severe to severe withdrawal) 1

Reassessment and titration:

• Wait 30–60 minutes after the initial dose 1
• If withdrawal symptoms persist, administer 2–4 mg additional doses every 2 hours 1
• Target a Day 1 total of approximately 8 mg (acceptable range 4–8 mg) 1

The American College of Emergency Physicians notes that most patients require 8 mg on Day 1, though some stabilize at 4 mg 1. Rapid dosage increases on Day 1 are unnecessary for outpatients and carry risk for respiratory depression 3.

Day 2 and Maintenance Dosing

• Day 2: increase to 16 mg sublingual once daily 1
• Standard maintenance: continue 16 mg daily for most patients 1
• Dose range: 4–24 mg daily is acceptable, but 16 mg occupies approximately 95% of mu-opioid receptors and provides the ceiling effect on respiratory depression 1, 4

The 16 mg maintenance dose is supported by pharmacologic evidence showing near-maximal receptor occupancy and optimal treatment retention 1. Doses below 16 mg often result in persistent withdrawal symptoms and treatment failure 1.

Special Populations and Timing Considerations

Methadone-maintained patients:

• Wait >72 hours after the last methadone dose before giving any buprenorphine 1
• Methadone's long half-life (up to 30 hours) creates higher risk for severe precipitated withdrawal 1
• Strongly consider continuing methadone instead of switching, as both have similar effectiveness for withdrawal management 1

Fentanyl users:

• Despite the 12-hour minimum wait for short-acting opioids, fentanyl (especially analogs) may require longer intervals 5
• Recent case reports document precipitated withdrawal occurring even when COWS ≥8 at induction in fentanyl users 5
• If precipitated withdrawal occurs, the primary treatment is to give more buprenorphine (not less), with additional 2–4 mg doses every 1–2 hours until symptoms resolve 1, 5

A 2022 case report demonstrated successful management of fentanyl-related precipitated withdrawal by rapidly escalating to 20 mg total buprenorphine on Day 1, with complete symptom resolution 5.

Management of Precipitated Withdrawal

If precipitated withdrawal occurs despite following the protocol:

• Primary treatment: administer additional buprenorphine (2–4 mg every 1–2 hours) to re-establish adequate receptor occupancy 1, 5

• Adjunctive symptomatic management:

  • Clonidine 0.1–0.2 mg every 6–8 hours for autonomic symptoms (sweating, tachycardia, hypertension) 1
  • Antiemetics (promethazine or ondansetron) for nausea and vomiting 1
  • Benzodiazepines for anxiety and muscle cramps 1
  • Loperamide for diarrhea 1

The pharmacologic rationale for giving more buprenorphine is that higher doses eventually saturate receptors and provide sufficient agonist activity to suppress withdrawal 5.

Discharge Planning and Prescribing

• Prescribe 16 mg sublingual daily for 3–7 days or until the first follow-up appointment 1
• The X-waiver requirement was eliminated in 2023, allowing any DEA-licensed provider to prescribe buprenorphine-naloxone 1
• Non-waivered providers can administer (but not prescribe) buprenorphine for up to 72 hours while arranging referral 1

Mandatory discharge components:

• Provide a take-home naloxone kit and overdose-prevention education 1
• Offer hepatitis C and HIV screening 1
• Consider reproductive health counseling 1

Common Pitfalls to Avoid

• Starting buprenorphine when COWS <8 is the most common error and will precipitate severe withdrawal 1

• Giving the first dose too soon after methadone (<72 hours) causes prolonged precipitated withdrawal that is difficult to reverse 1

• Prescribing discharge doses below 16 mg daily leads to persistent withdrawal symptoms and treatment failure 1

• Discontinuing buprenorphine once started precipitates withdrawal and dramatically increases relapse risk to more dangerous opioids 1

The CDC explicitly recommends offering buprenorphine as medication-assisted maintenance rather than detoxification, because maintenance better prevents relapse 1. There is no maximum recommended duration for buprenorphine maintenance—patients may require treatment indefinitely 1.

Evidence Quality and Comparative Effectiveness

A 2025 systematic review of 26 studies (n=4,497) found the overall incidence of buprenorphine-precipitated withdrawal ranged from 0% to 13.2%, with most studies reporting rates below 5% when proper protocols are followed 6. The American College of Emergency Physicians assigns Level B evidence (moderate quality) to the recommendation for buprenorphine over alpha-2 agonists, based on significantly lower withdrawal scores and higher treatment completion rates (NNT=4) 1.

Buprenorphine demonstrates clear superiority over clonidine or lofexidine for opioid withdrawal management 1. Methadone has similar efficacy to buprenorphine but is less commonly used in acute settings due to regulatory restrictions 1.